Do we know the Th1/Th2/Th17 determinants of vaccine response?

Expert Review of Vaccines

Volumn 11, Issue 11, 2012, Pages 1307-1310

  Garlapati, Srinivas ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

adjuvant; delivery system; immunomodulator; synchronization; T cell polarization

Indexed keywords

EID: 84877135441     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.111     Document Type: Article

References (17)

1. P., Nordly, F., Rose, D., Christensen, et al., Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method, J. Control. Release, (2011), 150, 3, 307-317
2. Salvador A, Igartua M, Hernández RM, Pedraz JL. An overview on the field of micro- and nanotechnologies for synthetic peptide-based vaccines. J. Drug Deliv. 2011, 181646 (2011).
3. Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat. Immunol. 12 (6), 509 – 517 (2011).
4. Kamath AT, Rochat AF, Christensen D et al. A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells. PLoS ONE 4 (6), e5771 (2009).
5. Fomsgaard A, Karlsson I, Gram G et al. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. Vaccine 29 (40), 7067 – 7074 (2011).
6. Martel CJ, Agger EM, Poulsen JJ et al. CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets. PLoS ONE 6 (8), e22891 (2011).
7. Pinto VV, Salanti A, Joergensen LM et al. The effect of adjuvants on the immune response induced by a DBL4e-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria. Vaccine 30 (3), 572 – 579 (2012).
8. Rosenkrands I, Vingsbo-Lundberg C, Bundgaard TJ et al. Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine 29 (37), 6283 – 6291 (2011).
9. Yu H, Karunakaran KP, Jiang X, Shen C, Andersen P, Brunham R.C. Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice. Infect. Immun. 80 (4), 1510 – 1518 (2012).
10. Kamath AT, Mastelic B, Christensen D et al. Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses. J. Immunol. 188 (10), 4828 – 4837 (2012).
11. Joffre O, Nolte MA, Spörri R, Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev. 227 (1), 234 – 247 (2009).
12. Christensen D, Henriksen-Lacey M, Kamath AT et al. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. J. Control. Release 160 (3), 468 – 476 (2012).
13. Henriksen-Lacey M, Christensen D, Bramwell VW et al. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N′,N′-dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses. Mol. Pharm. 8 (1), 153 – 161 (2011).
14. Aebig JA, Mullen GE, Dobrescu G et al. Formulation of vaccines containing CpG oligonucleotides and alum. J. Immunol. Methods 323 (2), 139 – 146 (2007).
15. Garlapati S, Eng NF, Kiros TG et al. Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. Vaccine 29 (38), 6540 – 6548 (2011).
16. Garlapati S, Eng NF, Wilson HL et al. PCPP (poly[di(carboxylatophenoxy)-phosphazene]) microparticles co-encapsulating ovalbumin and CpG oligo-deoxynucleotides are potent enhancers of antigen specific Th1 immune responses in mice. Vaccine 28 (52), 8306 – 8314 (2010).
17. Christensen D, Foged C, Rosenkrands I et al. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Int. J. Pharm. 390 (1), 19 – 24 (2010).